Clinical Trial

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-11; most recent amendment 2025-04-23.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-04-23
Trial Details
NCT Number NCT06315426
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Allergic Rhinitis
Enrollment 240 participants
Start Date 2024-03-24
Primary Completion 2025-05 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-25